ClearPoint Neuro Wins Canadian Medical Device License for Navigation, Expands 34-Country Network
ClearPoint Neuro received a Health Canada Medical Device License for its Neuro Navigation covering MRI and iCT workflows, building on SmartFlow Neuro Cannula clearance from October 2025. This enables standardized cell and gene therapy at Canadian academic and commercial sites, expanding ClearPoint’s 34-country platform and supporting its 20,000-procedure annual target.
1. Canadian Approval Details
ClearPoint Neuro received a Medical Device License from Health Canada for its Neuro Navigation System, covering both MRI-guidance and iCT-guidance workflows. This clearance follows the October 2025 approval of the SmartFlow Neuro Cannula and completes the platform’s regulatory package in Canada.
2. Strategic Impact on Trials
The full-platform approval enables Canadian academic medical centers and biopharma partners to deploy standardized navigation and delivery workflows in clinical and commercial settings. Consistent procedures are expected to reduce trial complexity, minimize surgical variability, and accelerate cell and gene therapy development in Canada.
3. Global Infrastructure Expansion
Canada now joins ClearPoint’s existing 34-country network for integrated navigation and therapy delivery solutions. The expanded regulatory footprint supports the company’s strategy to enable 20,000 annual cell and gene therapy procedures and strengthens its global commercial infrastructure.